<DOC>
	<DOCNO>NCT00398424</DOCNO>
	<brief_summary>This Phase I , Open-Label study evaluate PK S-1 component metabolites patient advance solid tumor vary degree hepatic function define NCI classification hepatic impairment . Patients stratify 4 Cohorts- Normal , Mild , Moderate Severe . Six patient enrol inot cohort receive S-1 .</brief_summary>
	<brief_title>Evaluating Patients With Impaired Hepatic Function</brief_title>
	<detailed_description />
	<criteria>A patient must meet follow inclusion criterion eligible enrollment study : 1 . Has histologically cytologically proven advanced solid tumor standard therapy exists . 2 . Has provide write informed consent . 3 . Is 18 year age old . 4 . Is able take medication orally . 5 . Has Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 ≤ 2 ( Appendix A , ECOG Performance Status ) . 6 . Has adequate organ function define follow criterion : 1 . Absolute granulocyte count ≥ 1,500/mm3 ( ie , ≥ 1.5 x 109/L International Units [ IU ] ) . 2 . Has platelet count ≥ 100,000/mm3 ( IU : ≥ 100 x 109/L ) . 3 . Has hemoglobin value ≥ 9.0 g/dL . 4 . Has calculate creatinine clearance &gt; 60 mL/min ( CockcroftGault 7 . Is willing able comply schedule visit , treatment plan , laboratory test , study procedure . Exclusion Criteria Exclude patient study he/she fulfill inclusion criterion , follow condition observe : 1 . Has treatment follow within specified time frame prior study drug administration : 1 . Any investigational agent receive either concurrently within last 30 day . 2 . Previous therapy malignancy within 21 day , include chemotherapy , immunotherapy , biologic hormonal therapy ( 6 week nitrosoureas mitomycin C ) . 3 . Previous radiotherapy within 14 day . 4 . Current enrollment another clinical trial . 5 . Required shunt stenting liver within prior 28 day plan first study treatment cycle . 2 . Has serious illness medical condition ( ) include , limited , follow : 1 . Myocardial infarction within last 6 month , severe/unstable angina , congestive heart failure ( New York Heart Association [ NYHA ] Class III IV , see Appendix F , NYHA Classification ) . 2 . Known ( time entry ) gastrointestinal disorder , include malabsorption , chronic nausea , vomit , diarrhea present extent might interfere oral intake absorption study medication . 3 . Previous organ allograft , include liver transplantation . 4 . Known brain metastasis . 5 . Known leptomeningeal metastasis . 6 . Manifest ascites . 7 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness . 8 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment Investigator would make patient inappropriate entry study . • 3 . Is receive concomitant treatment drug interact S1 . The following drug prohibit may interaction S1 : 1 . Sorivudine , uracil , dipyridamole , cimetidine folinic acid ( may enhance S1 activity ) . 2 . Allopurinol ( may diminish S1 activity ) . 3 . Phenytoin ( S1 may enhance phenytoin activity ) . 4 . Flucytosine , fluorinated pyrimidine antifungal agent ( may enhance S1 flucytosine activity ) . 5 . Pilocarpine ( may inhibit CYP2A6 activity ) . 4 . Has know sensitivity 5FU . 5 . Is pregnant lactate female . 6 . Is patient reproductive potential refuse use adequate mean contraception ( include male patient ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Impaired Hepatic Function</keyword>
</DOC>